STOCK TITAN

Early Warning Press Release in Respect of Atmofizer Technologies Inc.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

TORONTO--(BUSINESS WIRE)-- SOL Global Investments Corp. (the “Company” or “SOL Global”) (CSE: SOL) (OTCQ SOLCF) (Frankfurt: 9SB) announces that on February 3, 2022, the Company disposed of an aggregate of 1,300,000 common shares (each a “Common Share”) of Atmofizer Technologies Inc. (“Atmofizer”) (the “Disposition”). As a result of the Disposition, SOL Global now holds less than 10% of the issued and outstanding Common Shares on a partially diluted basis.

Immediately prior to the Disposition, SOL Global held 7,139,200 Common Shares and 1,299,999 Common Share purchase warrants (“Warrants”), representing 10.30% of the issued and outstanding Common Shares on a partially diluted basis. Immediately following the Disposition, SOL Global held a remaining 5,839,200 Common Shares and 1,299,999 Warrants, representing approximately 8.71% of the issued and outstanding Common Shares on a partially diluted basis.

SOL Global may, depending on market and other conditions, increase or decrease its beneficial ownership in Atmofizer’s securities, whether in transactions on the open market, by privately negotiated arrangements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities.

As of the date hereof, SOL Global no longer beneficially owns nor controls 10% or more of the issued and outstanding Common Shares. Accordingly, SOL Global is no longer required to file early warning reports pursuant to the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues unless SOL Global’s beneficial ownership or control of the Common Shares again increases above 10% of the issued and outstanding Common Shares of the Company.

This news release, and the early warning report filed in connection with the Disposition, was filed late due to administrative error.

An early warning report prepared pursuant to the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues by SOL Global has been filed on SEDAR at www.sedar.com under the Atmofizer’s profile. To obtain more information or to obtain a copy of the early warning report to be filed in respect of this news release, please contact SOL Global at the contact details noted below.

About SOL Global Investments Corp.

SOL Global is a diversified investment and private equity holding company engaged in the small and mid-cap sectors. SOL Global’s investment partnerships range from minority positions to large strategic holdings with active advisory mandates. The Company’s seven primary business segments include Retail, Agriculture, QSR & Hospitality, Media Technology & Gaming, and New Age Wellness.

The Company’s head office is located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9.

SOL Global Investments Corp.

Paul Kania, Chief Financial Officer

Phone: (212) 729-9208

Email: info@solglobal.com

Source: SOL Global Investments Corp.

SOL Global Investments Corp

OTC:SOLCF

SOLCF Rankings

SOLCF Latest News

SOLCF Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Miscellaneous Commercial Services, Commercial Services
Canada
Toronto

About SOLCF

scythian is a pharmaceutical development company currently undertaking pre-clinical testing at the university of miami on a combination drug therapy for the treatment of traumatic brain injury ("tbi") and concussion. tbi happens when there is a major impact to the head or subjected to accelerative forces. it frequently results in both initial damage from the impact itself and significant subsequent damage from inflammation and the body's own immune response. a significant amount of brain injury occurs from the inflammatory and immune response. scythian’s pharmaceutical approach aims to reduce both the inflammation and the immune response by using a combination of two drugs as the acute emergency room or post injury treatment. a broad based u.s. provisional patent application has been filed utilizing drug combinations which affect the endocannabinoid pathway to treat concussions. scythian's second business line is its application to become a licensed producer of medical marijuana in can